GENE ONLINE|News &
Opinion
Blog

Gilead Sciences
M&A Gilead Sciences
Gilead Sciences Acquires CymaBay for $4.3 billion, Heralding a New Era in PBC Treatment
2024-02-15
Trials & Approvals CAR-T therapyCAR T-cell Therapy
FDA Boxed Warning for CAR-T therapy, Affecting Bristol-Myers Squibb, Novartis, Janssen, Gilead Sciences
2024-01-24
PRNEWSWIRE Gilead SciencesHepatitis B VirusHepatitis C Virus
GILEAD LAUNCHES GLOBAL ALL4LIVER GRANT PROGRAM TO HELP ACHIEVE THE WORLD HEALTH ORGANIZATION’S GOAL OF VIRAL HEPATITIS ELIMINATION BY 2030
2023-07-28
Trials & Approvals Gilead Sciences
Gilead’s HDV Drug Headed Towards European Approval Even With FDA Rejection
2023-05-08
GILEAD TO PRESENT DATA AT APASL 2023 ON EFFECTIVE MODELS FOR MONITORING AND TREATING HEPATITIS C AND EFFICACY OF ANTIVIRAL TREATMENTS FOR HIV-1 AND HBV-COINFECTED ADULTS
2023-02-14
Deals Gilead Sciences
Jounce Sells Anti-CCR8 Antibody to Gilead, Forgoing $645 Million In Milestones
2022-12-28
Trials & Approvals NSCLC
Gilead, Arcus’ Anti-TIGIT Combinations Show Survival Advantage Over Anti-PD1 Monotherapy In Phase 2 Trial
2022-12-20
Trials & Approvals hepatitis B
The FDA Expands Use for Gilead Science’s HBV Treatment
2022-11-02
Trials & Approvals HIV
Gilead Touts Long-Term Efficacy And Safety Data For HIV Drug
2022-10-26
Licensing Kite Pharma
Kite to Use Refuge’s Gene Expression Platform for New CAR-T Therapies
2022-10-21
Partnerships Bispecific Antibody
Gilead and MacroGenics Strike Potential $1.7 billion Collaboration Over Bispecific Antibodies
2022-10-17
Trials & Approvals Breast Cancer
Action Date Set for Gilead Sciences’ HR+/HER2- breast cancer sBLA
2022-10-11
Trials & Approvals B-cell Lymphoma
CHMP Gives Kite’s Lymphoma Immunotherapy a Positive Opinion
2022-09-16
Trials & Approvals HIV
Gilead’s Novel Capsid Inhibitor Treatment for HIV Gains First Approval from European Commission
2022-08-22
Licensing Gilead Sciences
Gilead Forking Over $280 million to Everest to Regain Rights to Breast Cancer Treatment
2022-08-16
1 2 3 … 5
LATEST
Eli Lilly’s Orforglipron Shows Phase 3 Success: First Oral GLP-1 Drug for Type 2 Diabetes and Weight Loss
2025-04-21
Dupixent Makes History with FDA Approval as First New CSU Treatment in Over a Decade
2025-04-20
Multiple PCV Doses May Be Needed for Immunocompromised Type 2 Diabetics to Maintain Protection, Study Finds
2025-04-19
Multiple PCV Doses May Be Needed for Immunocompromised Individuals with Type 2 Diabetes
2025-04-19
Dr. Lauren Krupp, FAAN, Advocates Early Intervention and Family Support in Pediatric MS Treatment.
2025-04-19
Dr. Lauren B. Krupp Recommends Early, Aggressive Treatment with High-Efficacy Therapies for Pediatric Multiple Sclerosis
2025-04-19
GSK’s Blenrep Scores World-First Approval in UK for Multiple Myeloma
2025-04-17
READ MORE
EVENT
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
2025-04-26
SABPA OC/LA 17th Annual Biomedical Forum
Irvine, California, United States
2025-05-03
29th Taiwan Joint Cancer Conference 2025
Taipei, Taiwan
2025-05-05
Swiss Biotech Day 2025
Basel, Switzerland
SEE MORE
Newsletter

Subscribe to receive updates.

SIGN UP
Facebook
Youtube
Twitter
Linkedin
About
Explore
More
© 2025 GeneOnline
Privacy Policy | Terms of Service
Privacy Policy | Terms of Service
  • Subscribe to our newsletter and dive into the world of biopharma with us.
SIGN UP
x
Scroll to Top